Economics and Statistics Research Journal (ESRJ)
Volume.16, Number 5; May-2025;
ISSN: 2836-8398 | Impact Factor: 9.97
https://zapjournals.com/Journals/index.php/esrj
Published By: Zendo Academic Publishing

CONTROLLED TRIAL ON PROLONGED LOSARTAN POTASSIUM USE IN RELATION TO CANCER

[1]Audi Najib Isyaku, [1]Mary U. Adehi, [1]Nweze Obini Nweze, [1]Bilkisu Maijama'a, [1]Saidu Rabo Yahaya and [1]Yahaya Muhammad Musa.

Article Info

Keywords: Antihypertensive drugs, cancer risk, meta-analysis, systematic review, randomized controlled trials, hypertension, pharmacovigilance

DOI

10.5281/zenodo.15525243

Abstract

Background: The potential association between antihypertensive drug use and cancer risk is a subject of debate. Although antihypertensive medications are crucial for managing hypertension, concerns have arisen regarding their long-term effects, including carcinogenic potential. This study conducts a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the risk of cancer associated with antihypertensive drug use.

Methods: A comprehensive literature search was performed using multiple databases to identify relevant RCTs. Studies assessing the relationship between antihypertensive drug use and cancer incidence were included. A meta-analysis was conducted using fixed and random-effects models, and heterogeneity among studies was assessed using Cochran's Q and I^2 statistics. Sensitivity and subgroup analyses were performed to examine variations in risk across different drug classes.

Results: Data from multiple trials, including large-scale cohort studies, revealed heterogeneous findings. The meta-analysis of various antihypertensive drugs revealed mixed associations with cancer risk. Some studies have indicated a statistically significant increase in cancer risk, particularly with drugs such as calcium channel blockers and angiotensin receptor blockers (ARBs). Notably, the pooled odds ratio (OR) for the fixed-effects model suggested a modest but significant increase in cancer risk (OR: 1.27, 95% CI: 1.09–1.47, p=0.001). Losartan potassium use was associated with a varied cancer risk, with some studies reporting elevated risk ratios, such as Ranpura et al. (2011) (RR: 5.28, 95% CI: 4.15–6.71, p=0.001). Similarly, amlodipine besylate studies presented inconsistent results, with some reporting a significant association (e.g., Kumar et al., 2020, OR: 1.38, 95% CI: 1.23–1.53, p=0.95). Heterogeneity analysis (I^2 = high) revealed considerable variation in study outcomes. Funnel plot assessment revealed potential publication bias.

Conclusion: This meta-analysis provides evidence of a possible association between specific antihypertensive medications and cancer risk although the findings remain inconclusive due to heterogeneity and potential confounding factors. Further large-scale high-quality RCTs with extended follow-up periods are needed to clarify this relationship. Physicians should weigh the benefits of antihypertensive therapy against potential risks, emphasizing individualized assistance.

[1]Department of Statistics, Nasarawa State University, Keffi, Nigeria.
Email: najibaudi@nsuk.edu.ng

INTRODUCTION

In 2017, hypertension was identified as a major risk factor for cardiovascular disease globally, accounting for 9.39–11.5 million deaths and 198–237 million disability-adjusted life years (Stanaway, 2018). Fortunately, antihypertensive therapy significantly reduces the risk of cardiovascular disease and death in various populations. A meta-analysis showed that reducing systolic blood pressure by 10 mm Hg would reduce the risk of major cardiovascular disease, coronary heart disease, stroke, and heart failure by 17% to 28%, whereas all-cause mortality was reduced by 13% (Yuxiu Xie, 2021).

As an effective measure to control blood pressure, antihypertensive medications are commonly prescribed worldwide, and many patients take these drugs as prescribed by their physician, usually over a long period of time. Hypertension is the most important risk factor for cardiovascular and all-cause mortality worldwide, accounting for 10.8 million deaths every Year (Raebel, 2021).

Antihypertensive medications, such as thiazide, beta-blockers, calcium channel blockers, and alpha-blockers, are widely used to treat hypertension as well as other conditions, such as heart disease, heart failure, and stroke, and lower morbidity and mortality (Mukete, et al., 2015). Thiazide diuretics are considered first-line agents for the treatment of hypertension (H. Esh, 2023).

The potential carcinogenic effect of hydrochlorothiazide may be explained by its photosensitizing properties, which increase the risk of skin cancer (Monteiro, et al., 2016). However, drug-induced photosensitivity has also been reported for other thiazide diuretics, loop diuretics, calcium channel blockers, angiotensin-converting-enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) (A.F. Monteiro, 2016).

Drug-induced photosensitivity indicates an adverse reaction of the skin caused by the combination of sun exposure and a pharmaceutical compound of antihypertensive drugs. Compounds of the antihypertensive medication in the skin are excited by UV radiation, leading to the formation of reactive oxygen species (ROS). This can not only lead to photogenotoxicity but can also activate immune cells and induce the release of cytokines (Kreutz R., 2019).

As the mortality risk of untreated hypertension is substantially higher than that of well-monitored skin cancer, discontinuation of adequate antihypertensive treatment may increase mortality. In this respect, the potential carcinogenicity of an antihypertensive drug needs to be carefully weighed against the potential carcinogenicity of other antihypertensive drug classes and their blood pressure-lowering effects (Heisel et al., 2023).

Hypertension is a major risk factor for cardiovascular disease (CVD) and is significantly associated with increased morbidity and mortality from CVD (Calvillo L, 2019). Left ventricular hypertrophy (LVH) is a common target organ damage associated with hypertension, which can cause abnormal changes in the ultrastructure and energy metabolism of cardiomyocytes, resulting in adverse cardiovascular events, such as abnormal Cardiac contraction, diastolic function, and arrhythmia(Yildiz M, 2020). The left ventricular mass index (LVMi), which reflects LVH, plays an important role in predicting the risk of future adverse cardiovascular events in the future(Park SK, 2019).The European Society of Cardiology (ESC) European Society of Hypertension (ESH) 2018 Guidelines for Hypertension Diagnosis and Treatment indicate that antihypertensive therapy reverses LVH As represented by a reduction in cardiovascular events and mortality (Williams B, 2018).

Based on preliminary clinical studies, the American expert consensus on hypertension indicates that angiotensin receptor blockers (ARB) or angiotensin-converting enzyme inhibitors (ACEI) are generally used in hypertensive patients with LVH (Whelton, et al., 2018).

Although evidence for the benefits of antihypertensive medication in the prevention of cardiovascular disease has been well established, (Turnbull F, 2003). Low treatment adherence is a major barrier to effective blood pressure control (Marshall IJ, 2012). Noncompliance with antihypertensive medication is often due to concerns about possible adverse effects, including an increased risk of developing cancer (Gascón JJ, 2004). Several pathways have been hypothesized to explain possible associations between raised blood pressure and cancer risk, but the findings have been inconsistent and mainly based on observational studies (Seretis et al., 2019). Most concerns have been associated with the off-target effects of specific drug classes, such as possible carcinogenic effects of angiotensin II receptor blockers (ARBs) on lung issues and the photosensitizing effect of thiazide diuretics that could increase the susceptibility of the skin to the effects of sunlight exposure (Kreutz R, 2019).

A series of meta-analyses of randomized controlled trials based on aggregate data have investigated the association between class-specific antihypertensive treatment and cancer risk, but the findings have been conflicting. One study suggested that the use of ARBs increases the risk of cancer, (Yujiao Deng, 2022), whereas two subsequent meta-analyses showed no such association. In a study that found no consistent evidence that antihypertensive medication use had no effect on cancer risk. Although such findings are reassuring, evidence from some comparisons was insufficient to entirely rule out excess risk, particularly for calcium channel blockers (Copland et al., 2021). Another meta-analysis of randomized controlled trials found no evidence linking any drug class with the incidence of any cancer, (Bangalore et al., 2012), but an increased risk of cancer with the use of angiotensin-converting enzyme inhibitors (ACEIs) in combination with ARBs could not be ruled out.

METHODOLOGY

Research Design

The systematic literature search on the controlled trials of anti-hypertensive drugs and the risk of cancer using both fixed and random effects models was carried out using the following databases: Google Scholar, PubMed, Medline Scopus, Embase, and relevant journal of pharmaceutical, annals of cardiovascular, and journal of therapeutic and pharmacology. Where meta-analysis was conducted, the studies met the following criteria:

I. The burden of hypertension in Nigeria
II. Controlled trial of anti-hypertensive drugs in Relation to cancer
III. Controlled trials on the use of Losatarn, and Amlodipine and their potential association with cancer risk
IV. Hazard ratio

Relevant parameters from the included studies were recorded in standardized form. Meta-analysis involves pooling data across the included studies. This started with extracting and appropriately recording the mathematical requirements for the Meta-Analysis. These include SE (which in this case is the anti-hypertensive drugs and their trials concerning the risk of cancer), 95% confidence interval (CI) of the impact, log of the impact, and the standard error (SE) of the log of the impact. It is important to note here that the SE may be computed if CI is available by backward computation from equations (Lee, C., et al., 2016). In this case, the two equations are solved as simultaneous linear equations, and we solve for SE. Information recorded in the first and second parts of the study were used to compute the quality of the articles that met the outlined inclusion criteria as such, satisfying the recommendations of the Preferred Reporting Items for and Meta-analysis (PRISMA) as it is provided (DerSimonian, R., et al., 2015)

Data Search for a Controlled Trial on the Prolonged Use of Losartan Potassium in Relation to Cancer

Data was sourced through literature searches, and 15 studies (Fig2) were included in the meta-analysis. Therefore, the inclusion criteria were studies that included, Odd Ratios, Sample Size (Number Patient) and Fixed and Random effect model.



Figure 1: Flow Chart Showing Data Extraction on Controlled Trial of Prolonged use of Losartan Potassium in Relation to Cancer



Figure 2: Flow Chart Showing Data Extraction on Controlled trials on the use of Amlodipine besilate and its potential association with cancer risk.

Method for estimating mean and variance for fixed- and random-effects met analysis

The DerSimonian and Laired (1986) methods are based on standard fixed or random-effects models, and the methods have been expanded to provide a solution to the meta-analysis Controlled trial of anti-hypertensive drugs in Relation to risk of cancer. Consider a collection of k-controlled trial-related studies on antihypertensive drugs and risk of cancer, i[th] of which the estimated size Yi and the true effect size ϑ_i, the general models are as follows:

$$Y_1 = \begin{cases} \vartheta + E_i & fixedeffect \\ \mu + \vartheta_i + e_i & randomeffect \end{cases} \quad (3.1)$$

Where

$$E_i and e_i \sim N(0, \sigma_i^2), i = 1,2, \dots, k$$

$E_i$is the sampling error, and

e_i is the random deviation of the study's observed effect from the true effect size.

$\vartheta$is the population mean.

$\vartheta_i$is the true effect size, and

$\mu$is the grand mean of the

Let $y_i = y_1, y_2, \dots, y_k$ be effect sizes for k studies, and $f(y_i, \vartheta, \sigma_i^2)$ a parametric density for some random quantity y, where ϑ is a parameter of interest and σ_i^2 is a nuisance parameter that may not be present in the model. The following assumptions are made:

1. $f(y_i, \vartheta, \sigma_i^2)$ is assumed to be the normal density (for available measures, $y_i, I = 1, 2, 3, \dots, k$).
2. Heterogeneity distribution (P) is assumed to be normal with parameters, μ and τ^2.
3. Individual study variances are known.
4. The marginal distribution is normal with parameters μ and $\hat{\sigma}_i^2 + \tau^2$.
5. $\vartheta$is not a constant.

The fixed-effects model assumes $\vartheta_i = \mu$ for $i = 1, 2, \dots, k$, implying that each study in the meta-analysis has the same underlying effect. The estimator of μ is generally a simple weighted average of the Y_i, with the optimal weights being equal to the inverse of the variance and

$$W_i = \frac{1}{V_{Y_i}} \quad (3.2)$$

Where V_{Y_i} is within the variance of study i.

The weighed mean (M) was then computed as

$$M = \frac{\sum_{i=1}^{k} W_i Y_i}{\sum_{i=1}^{k} W_i} \quad (3.3)$$

This is the sum of the products $W_i Y_i$ (effect size multiplied by weight) divided by the sum of the weights.

The variance of the summary effect is estimated as the reciprocal of the sum of the weights as follows:

$$V_M = \frac{1}{\sum_{i=1}^{k} W_i} \quad (3.4)$$

The estimated standard error of the summary effect is the square root of the variance as follows:

$$SE_M = \sqrt{V_M} (3.5)$$

Then, $(1 - \alpha)\%$ lower and upper limits for the summary effect are estimated as follows:

$$\left.\begin{aligned} LL_M &= M - t_{(1-a/2)} \times SE_M \\ UL_M &= M + t_{(1-a/2)} \times SE_M \end{aligned}\right\} (3.6)$$

Finally, the t-test to test the null hypothesis that ϑ is zero can be computed as follows:

$$t = \frac{M}{SE_M} \quad (3.7)$$

For a one-tailed test, the p-value is given as follows:

$$P = 1 - \phi(t) \quad (3.8)$$

In which we chose positive if the difference was in the expected direction and negative otherwise, and for a two-tailed test by

$$P = 2[1 - \phi(t)] \quad (3.9)$$

To compute a study's variance under the random-effects model, we need to know both the within-study variance and τ^2, since the study's total variance is the sum of the two values.

Tau squared (τ^2) is estimated using the method of moments or the D & L, DerSimonian and Laird (1986). The parameter τ^2 is between the study variance (the variance of the effect size parameters across the population of studies.

T is an estimate for τ^2, it is possible that T is negative due to sampling error, but it is unacceptable as a value for τ^2, so we define;

$$\tau^2 = \begin{cases} TifT > 0 \\ 0\ ifT \leq 0 \end{cases} \quad (3.10)$$

LetT^2 be an estimator of. τ^2

$$T^2 = \frac{Q - df}{C} \quad (3.11)$$

Where

$$Q = \sum_{i=1}^{k} W_i Y_i^2 - \frac{\left(\sum_{i-1}^{k} W_i Y_i\right)^2}{\sum_{i=1}^{k} W_i} \quad (3.12)$$

$$df = k - 1$$

Where k is the number of studies, and

$$C = \sum_{i=1}^{k} W_i - \frac{\sum_{i-1}^{k} W_i^2}{\sum_{i=1}^{k} W_i} \quad (3.13)$$

From (3.2) under the random-effects model the weight assigned to each study is given by

$$W_i^{\cdot} = \frac{1}{V_{Y_i}^*} \quad (3.14)$$

Where $V_{Y_i}^*$ is the within-study variance from study I plus the between-study variance,τ^2.

$$V_{Y_i}^* = V_{Y_i} + T^2 \quad (3.15)$$

The weighted mean, M^*, is

$$M^* = \frac{\sum_{i=1}^{k} W_i^* Y_i}{\sum_{i=1}^{k} W_i^*} \quad (3.16)$$

The sum of the products (effect size multiplied by weight) is divided by the sum of the weights.

The I^2 – statistics is an alternative and stronger measure of heterogeneity than the Q-measure (Borenstein et al., (2009).

$$I^2 = \left(\frac{Q - df}{Q}\right) \times 100\% \qquad (3.17)$$

Use value of Q from (3.12)

Heterogeneity in the $I^2 -$ statistics may be termed low, moderate, or high based on the intervals $0 \leq I^2 < 25\%, 25\% \leq I^2 < 50\%, or I^2 \geq 50\%$ respectively (Borenstein et al, (2009).

Brockwell and Gordon (2001) estimates μ and τ^2 using maximum likelihood method (MLM) and obtained estimates similar to those in the D & L method.

$y_i \sim N\left(\mu(\vartheta_i^2 + \tau^2)\right), \qquad i = 1,2,3, \ldots, k$

The probability density function is given by

$$f(y_i) = \frac{1}{\sqrt{2\pi}(\vartheta_i^2 + \tau^2)^{\frac{1}{2}}} e - \frac{1}{2}\left(\frac{y_i - \mu}{\sqrt{(\vartheta_i^2 + \tau^2)}}\right)^2 \qquad (3.18)$$

Where,

y_i is the ith estimated effect size of the k studies.

ϑ_i^2 is the variance in the ith study

$\tau^2$is a measure of heterogeneity added to the variance in random-effects models.

The log-likelihood function is given by

$$\log L(\mu, \tau^2) = \frac{1}{2}\sum_{i=1}^{k} \log\left(2\pi\left((\vartheta_i^2 + \tau^2)\right)\right) - \frac{1}{2}\sum_{i=1}^{k} \frac{(y_i - \mu)}{(\vartheta_i^2 + \tau^2)'} \mu \epsilon R, \tau^2 \geq 0 \qquad (3.19)$$

Partially differentiate (3.2) with respect to μ and τ^2 then set the derivatives to zero.

$$L = \frac{1}{\sqrt{2\pi}(\vartheta_i^2 + \hat{\tau}^2)^{\frac{1}{2}}} \frac{1}{2}\left(\frac{y_1 - \mu}{\sqrt{(\vartheta_i^2 + \hat{\tau}^2)}}\right)^2 \cdot \frac{1}{\sqrt{2\pi}(\vartheta_2^2 + \hat{\tau}^2)^{\frac{1}{2}}} e - \frac{1}{2}\left(\frac{y_2 - \mu}{\sqrt{(\vartheta_2^2 + \hat{\tau}^2)}}\right)^2 \cdot \ldots \cdot \frac{1}{\sqrt{2\pi}(\vartheta_k^2 + \hat{\tau}^2)^{\frac{1}{2}}} e - \frac{1}{2}\left(\frac{y_k - \mu}{\sqrt{(\vartheta_k^2 + \hat{\tau}^2)}}\right)^2 \qquad (3.20)$$

$$L = e^{\frac{1}{2}\sum_{i=1}^{k} \frac{(y_i - \mu)^2}{(\vartheta_i^2 + \hat{\tau}^2)}} \prod_{i=1}^{k} \left(2\pi\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)\right)^{-\frac{1}{2}} \qquad (3.21)$$

$$\log L = -\frac{1}{2}\sum \frac{(y_i - \mu)^2}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)} - \frac{1}{2}\sum \log\left(2\pi\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)\right) \qquad (3.22)$$

$$\frac{\vartheta \log L}{\vartheta \mu} = 0,$$

Then

$$\sum \frac{(y_i - \mu)}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)} = 0 \qquad (3.23)$$

$$\sum \frac{y_i}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)} = \mu \sum \frac{1}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)} \qquad (3.24)$$

$$\hat{\mu} = \left. \sum_{i=1}^{k} \frac{y_i}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)} \middle/ \sum_{i=1}^{k} \frac{1}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)} \right. \tag{3.25}$$

Equation (3.25) is synonymous with equation (3.16)

$$\frac{\vartheta \log L}{\vartheta \tau^2} = -\frac{1}{2}\sum_{i=1}^{k} \frac{1}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)} + \frac{1}{2}\sum_{i=1}^{k} \frac{4\pi^2 (y_i - \mu)^2}{\left(2\pi\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)\right)^2} = 0 \tag{3.26}$$

$$\frac{\vartheta \log L}{\vartheta \tau^2} = -\frac{1}{2}\sum_{i=1}^{k} \frac{1}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)} + \frac{1}{2}\sum_{i=1}^{k} \frac{(y_i - \mu)^2}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)} = 0 \tag{3.27}$$

$$\frac{\vartheta \log L}{\vartheta \tau^2} = -\frac{1}{2}\sum_{i=1}^{k} \frac{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)^2} + \frac{1}{2}\sum_{i=1}^{k} \frac{(y_i - \mu)^2}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)} = 0 \tag{3.28}$$

$$\frac{\vartheta \log L}{\vartheta \tau^2} = -\frac{1}{2}\sum_{i=1}^{k} \left[\frac{(y_i - \mu)^2}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)^2} - \hat{\vartheta}_i^2 + \hat{\tau}^2 \right] = 0 \tag{3.29}$$

$$\tau^2 = \left. \sum_{i=1}^{k} \frac{(y_i - \hat{\mu})^2 - \vartheta_i^2}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)^2} \middle/ \sum_{i=1}^{k} \frac{1}{\left(\hat{\vartheta}_i^2 + \hat{\tau}^2\right)^2} \right. \tag{3.30}$$

The maximum likelihood estimates $\hat{\mu}$ and $\hat{\tau}$ are then

$$(\hat{\mu}, \tau^2) = \begin{cases} (\hat{\mu}, \tau^2) & if\ \tau^2 > 0 \\ (\hat{\mu}, 0) & if\ \tau^2 \leq 0 \end{cases} \tag{3.31}$$

Where $\hat{\mu}$the fixed-effects estimate of μ and τ^2 is a measure of heterogeneity.

Sensitivity Analysis

A meta-analysis will yield an accurate synthesis of the studies included in this analysis; however, if these studies are a biased sample of all relevant studies, then the mean effect computed by the meta-analysis will reflect this bias, which is generally known as publication bias.

Funnel plots are a visual tool for investigating publication and other biases in meta-analysis, it is a simple scatter plots of treatment effects estimated from individual studies (horizontal axis) against a measure of study size (vertical axis).

Begg's and Egger's tests are regression tests that are available to test for the funnel plot $V(\vartheta)$ asymmetry, and a direct method was provided as an alternative and easier approach in sensitivity analysis (SA) by Helton et al., (1985). This approximation follows the first-order Taylor series approximation and is applied to the dependent variable, say ϕ, as a function of the independent variables: $\vartheta = (\vartheta_1, \vartheta_2, \dots, \vartheta_n)$.

The variance of $\phi, V(\vartheta)$, is calculated using the general error propagation formula.

$$V(\vartheta) = \sum_{i=1}^{n} \left(\frac{\vartheta \phi}{\vartheta g}\right)^2 V(\phi_i) \tag{3.32}$$

The variance inϕ is utilized as a measure of uncertainty in model predictions, while the variance in ϑ_i, weighted by the first-order partial derivative of ϕ with respect to ϑ_i, provides a measure of model sensitivity to ϑ_i, deduced from the work of Helton et al., (1985). In this case, a model is defined together with its independent

and dependent variables, and probability density functions (PDFs) are assigned to each input parameter; an input matrix is then generated through the appropriate random sampling method.

If x and y have independent random errors $\delta x \; and \; \delta y,$ then the error in $z = x + y$ is

$$\delta z = \sqrt{\delta x^2 + \delta y^2} \qquad (3.33)$$

The error in $z = x \times y$ is

$$\frac{\delta z}{z} = \sqrt{\left(\frac{\delta x}{x}\right)^2 + \left(\frac{\delta y}{y}\right)^2} \qquad (3.34)$$

If $z = f(x)$ for some function f, then

$$\delta z = |f'(x)|\delta x \qquad (3.35)$$

Here, is the derivative of function f.

Equation (3.34) follows from equation (3.36):

$$z = x \times y \qquad (3.36)$$

$$\log z = \log x + \log y \quad (3.37)$$

$$\delta \log z = \sqrt{(\delta \log x)^2 + (\delta \log y)^2} \qquad (3.38)$$

$$\frac{\delta z}{z} = \sqrt{\left(\frac{\delta x}{x}\right)^2 + \left(\frac{\delta x}{y}\right)^2} \qquad (3.39)$$

We measure $x_1, x_2, \dots, x_n$ with uncertainties$\delta x_1, \delta x_2, \dots, \delta x_n$. The purpose of these measurements is to determine 1, which is a function of $x_1, x_2, \dots, x_n$

$q = f(x_1, x_2, \dots, x_n)$.

The uncertainty in q is then given by

$$\mu_x = \frac{1}{N}\sum_{i=1}^{N} x_i \qquad (3.49)$$

Furthermore,

$$\mu_y = \frac{1}{N}\sum_{i=1}^{N} y_i \qquad (3.50)$$

Define $Q_1 = f(x_i, y_i)$and $Q = f(\mu_x, \mu_y)$, then

$$Q_i = f(\mu_x, \mu_y) + (x_i - \mu_x)\left(\frac{\partial Q}{\partial y}\right)\Big|_{\mu_x}(y_i - \mu_y)\left(\frac{\partial Q}{\partial y}\right)\Big|_{\mu_y} + \text{higher order terms} \qquad (3.51)$$

Neglecting higher-order terms, we obtain

$$Q_i - Q = (x_i - \mu_x)\left(\frac{\partial Q}{\partial x}\right)\Big|_{\mu_x}(y_i - \mu_y)\left(\frac{\partial Q}{\partial y}\right)\Big|_{\mu_y} \qquad (3.52)$$

$$\partial_Q^2 = \frac{1}{N}\sum_{i=1}^{N}(Q_i - Q)^2 \qquad (3.53)$$

$$= \frac{1}{N}\sum_{i=1}^{N}(x_i - \mu_x)^2\left(\frac{\partial Q}{\partial x}\right)_{\mu x}^2 + \frac{1}{N}\sum_{i=1}^{N}(y_i - \mu_y)^2\left(\frac{\partial Q}{\partial x}\right)_{\mu y}^2 + \frac{2}{N}\sum_{i=1}^{N}(x_i - \mu_x)(y_i - \mu_y)\left(\frac{\partial Q}{\partial x}\right)_{\mu x}\left(\frac{\partial Q}{\partial y}\right)_{\mu y} \qquad (3.54)$$

$$= \sigma_x^2 \left(\frac{\partial Q}{\partial x}\right)_{\mu x}^2 + \sigma_y^2 \left(\frac{\partial Q}{\partial y}\right)_{\mu y} + 2\left(\frac{\partial Q}{\partial x}\right)_{\mu x}^2 + \left(\frac{\partial Q}{\partial y}\right)_{\mu y} \frac{1}{N}\sum_{i=1}^{N}(x_i - \mu_x)\left(y_i - \mu_y\right) \qquad (3.55)$$

If the measurements are uncorrelated, then the summation in equation (3.55) is zero, otherwise defined it as σ_{xy}.

$$\sigma_x^2 = \sigma_x^2 \left(\frac{\partial Q}{\partial x}\right)_{\mu x}^2 + \sigma_x^2 \left(\frac{\partial Q}{\partial y}\right)_{\mu y}^2 \qquad (3.56)$$

For uncorrelated errors, and

$$\sigma_x^2 = \sigma_x^2 \left(\frac{\partial Q}{\partial x}\right)_{\mu x}^2 + \sigma_x^2 \left(\frac{\partial Q}{\partial y}\right)_{\mu y}^2 + 2\left(\frac{\partial Q}{\partial x}\right)_{\mu x}^2 \left(\frac{\partial Q}{\partial y}\right)_{\mu y}^2 \sigma_{xy} \qquad (3.57)$$

For correlated errors.

Subgroup Analysis

Subgroup analysis is used to show how meta-analysis is used to compare the mean effect among different subgroups of studies (akin to analysis of variance in a primary study). In meta-analysis, we work with subgroups of studies rather than groups of subjects, and we use a variant of the t-test to compare the subgroup, or a variant of analysis of variance where the subgroups are more than two.

Where heterogeneity is present among studies in a set, we may wish to group the studies to identify the source of the noise. In this case, we shift our focus from the mean effect on the effect size variation.

The alternative methods we propose combine three computational models and three methods for comparing means, as discussed by Borenstein et al., (2009), and work well with 2 or more subgroups.

The two computational models are: -

1. Random effects using separate estimates of τ^2
2. Random effects using pooled estimates of τ^2

Each one of the two models can be presented in three methods for comparing the subgroups:

i. Z-test
ii. Q-test based on analysis of variance
iii. Q-test for heterogeneity

The task required involves computing the mean effect and variance for each subgroup and comparing the mean effect across subgroups. To achieve these tasks, we must perform a meta-analysis on the subgroups A and B and then perform a meta-analysis on the combined mean effects. Having done so, we can now compare the subgroups as follows:

Random-effects Model with Separate Estimator of τ^2

Using the random-effects model with separate estimates requires us to compute a different τ^2 for each subgroup to be meta-analyzed. Following the methods in equation (3.11) to (3.17), using random effect weights. If there are only two subgroups, say, $T_I^2 and\ T_{II}^2$ for both subgroups I and II respectively, obtain $Q_I, Q_{II}, and\ Q^*$ for subgroups I and II combined, using equation (3.12). where the subgroups are more than two, resort to the Q-test based on ANOVA, follow the steps of generating the ANOVA table as in the fixed model.

Random Effects with Pooled Estimate of τ^2

To estimate and pool τ^2 consider equation (3.11), compute C from equation (3.13), then sum each element (Q,df, and C) across subgroups and then perform the same computations from equation (3.11) to obtain T_{within}^2, which is set to zero if it is negative, since we cannot have a negative variance, but it may happen due to sampling error.

If only two subgroups I and II are the case, use the Z-test to compare the mean effects for subgroups I and II, as in the fixed-effects model method. However, where the subgroups were more than two, we used the Q-test based on ANOVA, following the methods already discussed, and applied the random effect weights based on a pooled estimate of τ^2.

The Q-test for heterogeneity may be used for subgroups, such as I and II, as a single study to test for heterogeneity, using the same formula that we are familiar with, to test the dispersion of single studies about the summary effect.

The Proportion of Variance Explained (R^2)

R^2in meta-analysis is defined as the proportion of the true variance explained by the covariates because the true variance is estimated as T^2.

$$R^2 = \frac{T^2_{explained}}{T^2_{total}} \qquad (3.58)$$

Or

$$R^2 = 1 - \left[\frac{T^2_{explained}}{T^2_{total}}\right] \qquad (3.59)$$

$0 \leq R^2 \leq 1$

R^2that falls outside the range of 0 to 1 is mainly due to sampling errors (Borenstein et al., 2009).

Calculating Effect Size and Heterogeneity

To choose an effect size, according to Borenstein et al., (2009), we consider the following are satisfied: -

1. The effect sizes of the different studies should be comparable to one another in the sense that they measure the same thing.
2. Estimates of the effect size should be computable from the information that is likely to be reported in published research reports without requiring re-analyzing of the raw data.
3. The effect size should have good technical properties such that its sampling distribution is known so that variances and CI(s) can be computed. It should be meaningful; otherwise, transformation to another metric may be required for presentation.

According to Borenstein et al., (2009), the effect size is a value that reflects the strength of a relationship between two variables and is the unit of currency in a meta-analysis. Each study should have an effect size that can be used to assess the consistency of the effect across studies and to compute the summary effect. The effect size could be the relative risk ration, impact of interventions, or relationship between two variables. It is represented by a square on the forest plot, with the location of the square representing both the direction and magnitude of the effect. Meta-analysis in medicine refers to the effect size as a treatment effect and may refer to odd rations, relative risk ratios, risk differences, standard mean differences, correlation coefficients, or single group summary (no relationship).

The prospective studies included in the meta-analysis reported effect sizes as well as confidence intervals; as such, effect sizes were simply expunged and used. However, if data are from a prospective study with two groups, the number of events or nonevents (a 2x2 contingency table) data may be represented as cells A, B, C, and D (table 3.1) to compute a risk ratio, odds ratio, or hazard ratio.

Table 1: 2x2 contingency table of outcomes.

	Events	Non-events	N
Treated	X_{11}	X_{12}	n_1
Control	X_{21}	X_{22}	n_2

Source: Borenstein et al., (2009).

$$RiskRatio = \frac{x_{11}/n_1}{x_{21}/n_2} \quad (3.72)$$

$$Log\ RiskRatio = \ln(RiskRatio) \quad (3.73)$$

$$V_{\log RiskRatio} = \frac{1}{x_{11}} - \frac{1}{n_1} + \frac{1}{x_{21}} - \frac{1}{n_2} \quad (3.59)$$

$$SE_{\log RiskRatio} = \sqrt{V_{log_{RiskRatio}}} \quad (3.60)$$

$$OddsRatio = \frac{x_{11}x_{22}}{x_{12}x_{21}} \quad (3.61)$$

$$\log OddsRatio = \ln(OddsRatio) \quad (3.62)$$

$$V_{\log OddsRatio} = \frac{1}{x_{11}} + \frac{1}{x_{12}} + \frac{1}{x_{21}} + \frac{1}{x_{22}} \quad (3.63)$$

$$SE_{\log OddsRatio} = \sqrt{V_{log_{OddsRatio}}} \quad (3.64)$$

The hazard ratio is the ratio of two hazard functions with respect to time (t).

$$HR(t) = \frac{\varphi_1(t, x_{11})}{\varphi_2(t, x_{21})} \quad (3.65)$$

The hazard function is given by

$$\varphi(t, x) = \lim_{\Delta t \to 0^+} \frac{P(t \le T < +\Delta t \backslash T \ge t, X = x)}{\Delta t} \quad (3.66)$$

If the summary data reported by the primary studies are based on means and standard deviations in two groups, the appropriate effect size will usually be either the raw difference in means, the standard difference in means, or the response ratio.

Let μ_1 and μ_2 be the true (population) means of the two groups, respectively. The population mean difference is defined as follows:

$$\Delta = \mu_1 - \mu_2 \quad (3.67)$$

Here, d is computed from studies that use independent groups, say two independent groups, and let $\bar{X}_1$ and $\bar{X}_2$ be the sample means of the two independent groups. Then,

$$D = \bar{X}_1 - \bar{X}_2 \quad (3.68)$$

Let S_1 and S_2 be the sample standard deviations of the two groups, and n_1 and n_2 be the sample sizes of the two groups, respectively. If we assume that the two population standard deviations are the same i.e. $\sigma_1 = \sigma_2 = \sigma$, then the variance of D is given by

$$V_D = \frac{n_1 + n_2}{n_1 n_2} S^2_{pooled} \quad (3.69)$$

Where

$$S^2_{pooled} = \sqrt{\frac{(n_1 - 1)S_1^2 + (n_2 - 1)S_2^2}{n_1 + n_2 - 2}} \quad (3.70)$$

If we do not assume equal standard deviations, then

$$V_D = \frac{S_1^2}{n_1} + \frac{S_2^2}{n_2} \quad (3.71)$$

In either case, the standard error of D

$$SE_D = \sqrt{V_D} \quad (3.72)$$

We can compute D from studies that used matched groups or pre-post scores, where pairs of participants are matched in some way, with the two members of each pair being assigned to different groups. The unit of analysis is the pair, and the advantage of this design is that each pair serves as its own control, reducing the error term and increasing the statistical power.

In the top estimate D, we need to have the difference score for each pair, from which we can obtain the mean difference $\bar{X}_{diff}$ and the standard deviation of these differences (S_{diff}), then

$$D = \bar{X}_{diff} \quad (3.73)$$

$$V_D = \frac{S^2_{diff}}{n} \quad (3.74)$$

Here, n is the number of pairs, and

$$SE_D = \sqrt{V_D} \quad (3.75)$$

Sometimes, a review will include studies that used matched groups. There is no technical barrier to using different study designs in the same analysis because the effect size (D) has the same meaning regardless of the study design. Therefore, we can compute the effect size and variance from each study using the appropriate formula and then include all studies in the same analysis.

If we have the mean and standard deviation for each set of scores, say A and B sets, we compute D as in equation (3.68).

The variance and standard error are computed as follows in equations (3.74) and 3.75).

The standard deviation of each score is given by

$$S_{diff} = \sqrt{S_1^2 + S_2^2 - 2 \times r \times S_1 \times S_2} \quad (3.76)$$

Here, r is the correlation between scores in matched pairs.

If $S_1 = S_2$ then

$$S_{diff} = \sqrt{2 \times S^2_{pooled}(1 - r)} \quad (3.77)$$

In either case, as r moves toward 1.0, the standard error of the paired difference will decrease, and when r = 0, the standard error of the difference is the same as it would be for a study with two independent groups, each of size n.

If there are different scales in the studies, we use different instruments (such as different psychological or educational tests) to assess the outcome. In this instance, the scale of measurement will differ from one study to another, and it would not be meaningful to combine raw mean differences.

In such cases, we can divide the mean difference in each study by that study's standard deviation to create an index (the standard mean difference) that would be comparable across studies.

Let μ_1 and σ_1, be the true population mean and standard deviation of the first group and let μ_2 and σ_2 be the true population mean and standard deviation of the other group, respectively. If, as is assumed in most parametric data analysis techniques, we assume equal variance, then $\sigma_1 = \sigma_2 = \sigma$, hence the standardized mean difference is defined as

$$\partial = \frac{\mu_1 - \mu_2}{\sigma} \quad (3.78)$$

We can compute d from studies that use independent groups as follows:

$$d = \frac{\bar{x}_1 - \bar{x}_2}{S_{within}} \quad (3.79)$$

Where $\bar{X}_1$ and $\bar{X}_2$ are sample means in the two groups, and S_{within} is the within-group standard deviation pooled across groups.

$$S_{within} = \sqrt{\frac{(n_1 - 1)S_1^2 (n_2 - 1)S_1^2}{n_1 + n_2 - 2}} \quad (3.80)$$

The sample estimate of the standardized mean difference is often called Cohen's d in research synthesis because its development can be traced to Cohen (1987).

The variance of d is given by

$$V_d = \frac{n_1 + n_2}{n_1 n_2} + \frac{d^2}{2(n_1 + n_2)} \quad (3.81)$$

The standard error of d follows equation (3.90).

d has the bias of overestimating the absolute value of δ in small samples. The bias can be removed by a simple correlation that yields an unbiased estimate of δ, called Hedge's g, Hedges (1981).

To convert d to Hedges' g, we use the correction factor J.

$$J = 1 - \frac{3}{4df - 1} \quad (3.82)$$

Here, df is the degree of freedom used to estimate S_{witin}, which for two independent groups is $n_1 + n_2 - 2$. When$df \geq 10$, there exist error of less than 0.007 and less than 0.035 percent, Hedges (1981).

$g = J \times d$

$$V_g = J^2 \times V_d \quad (3.83)$$

The standard error of g follows equation (3.90)

The correction factor (J) is always less than 1.0, so g will always be less than d in absolute value, and the variance of g will always be less than the variance of d. however, J will be very close to 1.0 unless df is very small i.e. <10.

The difference between d and g is usually trivial; thus, the inclusion of J is likely to make little practical difference and should be encouraged.

We can compute d and from studies that use pre-post scores or matched groups.

$$d = \frac{\bar{Y}_{diff}}{S_{within}} = \frac{\bar{Y}_1 - \bar{Y}_2}{S_{witin}} \quad (3.84)$$

Where

$$S_{within} = \frac{S_{diff}}{\sqrt{2(1 - r)}} \quad (3.99.1)$$

Here, r is the correlation between pairs of observations.

$$V_d = \left(\frac{1}{n} + \frac{d^2}{2n}\right) 2(1-r) \quad (3.85)$$

Here, n is the number of pairs.

Assume that the correlation is known or that it can be estimated with high precision; otherwise, estimate the correlation from related studies, and possibly perform a sensitivity analysis using a range of plausible correlations. Next, compute J with n-1 degrees of freedom, where n is the number of pairs, and then compute Hedge's g, V_g and SE_g. Similar to the raw mean difference, the effect size d or g in a standardized mean difference has the same meaning regardless of the study design.

For all studies designs, the direction of the effect ($\bar{X}_1 - \bar{X}_2$ *or* $\bar{X}_2 - \bar{X}_1$) is arbitrary, except that the researcher must decide on a convention and then apply this consistently.

If the primary study reports a correlation between two variables, the correlation coefficient itself may serve as the effect size. Most meta-analysis does not perform synthesis on the correlation coefficient because the variance strongly depends on the correlation. Rather, the correlation was converted to Fisher's Z-scale, and all meta-analysis are performed using the transformed values. The results, such as the summary effect and its CI, are then converted back to correlation for presentation.

The transformation from sample correlation r to Fisher's Z is expressed as follows:

$$Z = 0.5 \times \ln\left(\frac{1+r}{1-4}\right) \quad (3.99.3)$$

The variance of Z is given by

$$V_Z = \frac{1}{n-3} \quad (3.99.4)$$

When working with Fisher's Z, variance is not used for correlation. Rather, the Fisher's Z-score and its variance are used in the analysis, which yields a summary effect, confidence limits, and so on, in the Fisher's Z metric. Each of these values is converted back to correlation units using the following expression:

$$r = \frac{e^{2Z} - 1}{e^{2Z} + 1} \quad (3.99.5)$$

In a research domain where the outcome is measured on a physical scale (such as length, area or mass) and is unlikely to be zero, the ratio of the means in the two groups might serve as the effet size index. The response ratios, computations are carried out on a log scale. The log response ration and the standard error of the log response ratio were computed and used to perform all steps in the meta-analysis. Then, the result was converted back into the original metric.

The response ratio (R) was computed as

$$R = \frac{\bar{X}_1}{\bar{X}_2} \quad (3.99.6)$$

Where $\bar{X}_1$ *and* $\bar{X}_2$ are means say of group 1 and 2, and the log response ratio is computed as

$$\ln R = \ln\left(\frac{\bar{X}_1}{\bar{X}_2}\right) = \ln(\bar{X}_1) - \ln(\bar{X}_2) \quad (3.99.7)$$

The variance of the log response ratio is approximately

$$V_{\ln R} = S^2_{pooled}\left[\frac{1}{n_1(\bar{X}_1)^2} + \frac{1}{n_2(\bar{X}_2)^2}\right] \quad (3.99.8)$$

Where S_{pooled} is the pooled standard deviation and the approximate standard error is the square root of equation (3.99.8)

Revert back to response ratios

$$R = \exp(\ln R) \quad (3.99.9)$$

Furthermore,

$LL_R = \exp(LL_{\ln R})$

$$UL_R = \exp(LL_{\ln R}) \quad (3.99.10)$$

Where LL_R and UL_R represent the lower and upper limits, respectively.

The effect size for each study is bounded by a confidence interval (CI), reflecting the precision with which the effect size was estimated in that study.

The solid squares used to depict each of the studies vary in size, with the size of each square reflecting the weight assigned to the corresponding study when we compute the summary effect.

There is a relationship between studies' precision and their weight in the analysis. Studies with relatively good precision are assigned more weight, whereas those with poor precision are assigned less weight. Since precision is primarily driven by sample size, we can consider the studies as having a weighted sample size. The effect size should have a computable standard error for precision. The sample size is important in standardizing the standard error, and that is why the sample size, n, is involved in all the formulas for standardizing the effect sizes.

In the pictorial representation of a meta-analysis, a square shape is used to assign weight to each study predictor/s variable/s. the larger the square, the more weight is assigned and the smaller, the less weight is assigned. The summary effect of the meta-analysis is represented by a diamond shape bounded by a confidence interval that will be tested for significance and statistical power based on the stated hypothesis.

If the effect size is consistent across all the studies in a meta-analysis, we may focus on the summary effect. It is important to assess the dispersion of effect sizes from study to study and take such into account when interpreting data.

If the effect sizes vary modestly, the summary effect but note that the true effect in any given could be somewhat lower or higher than this value.

If the effect varies substantially from one study to the next, our attention will shift from the summary effect to the dispersion itself. The dispersion in observed effects includes both real differences in effects and random errors. It is important to partition the observed variance into the part due to error and the part representing variation in true effect sizes.

P-Values

For each study, the p-value for a null test is presented. There is a necessary correspondence between the p-value and the confidence interval, such that the p-value will fail under 0.05 if and only if the 95% confidence interval does not include the null. Obtaining a summary effect was the primary goal of the meta-analysis, and it is shown on the bottom of the forest plot (a pictorial presentation of the results of a meta-analysis). The summary effect is nothing more than the weighted mean of individual effects. The mechanism used to assign weights for a summary effect depends on the assumptions about the distribution of the effect sizes from which the studies were sampled; fixed effect models or random effect models.

Under the fixed effect model, the assumption is that all studies in the analysis share the same true effect size, and the summary effect is an estimate of this common effect size.

Under the random-effects model, the assumption is that the true effect size varies from study to study, and the summary effect is an estimate of the mean distribution of effect sizes.

RESULTS AND DISCUSSION

The findings of a systematic review and meta-analysis of randomized controlled trials assessing the risk of cancer associated with the use of antihypertensive drugs. The data presentation includes statistical results derived from the fixed- and random-effects models. The key parameters extracted from the selected studies include effect size (odds ratio), sample size, confidence intervals, and p-values.

Determine the risk of cancer associated with prolonged use of losartan potassium tablet and Amlodipine Basilate treatment of hypertension, using odd rations as the effect size.

Table 2: Data Presentation on Risk of Cancer Associated with the Use of Losartan Potassium Tablets for treating Hypertension

S/n	Study Name	Effect Size: Risk Ratio	Sample Size	Lower Confidence Level 95%	Upper confidence level of 95%	P Value
1	Iike et al. (2011)	1.01	10	0.95	1.07	0.78
2	Iike et al. (2010)	1.08	30014	1.01	1.15	0.016
3	Datzmann et al. (2019)	1.02	8818	0.87	1.19	0.003
4	Cao et al. (2018)	1.07	12	0.96	1.2	
5	Craig et al. (2008)	1.12	27	0.87	1.47	
6	Asgharzadeh et al. and Kesharazaian et al (2023)	0.723	9	0.568	0.921	0.009
7	Matteo et al. (2013)	0.33		0.13	0.83	0.019
8	Angelika et al. (2023)	0.98	12	0.86	1.11	0.7731
9	Victoria et al. (2018)	1.15	10	1.01	1.32	
10	Thakur et al. (2018)	1.14	11	1.02	1.27	0.02
11	Heng et al. (2015)	1.09	6463	103	1.16	0.003
12	Ranpura et al. (2011)	5.28	20	4.15	6.71	0.001
13	Sooyomg&Yoojih et al. (2018)	5.67	12	3.02	10.65	
14	Hedong et al. (2017)	1.15	29	1.08	1.22	
15	Pahor et al. (2000)	1.26	12699	1.11	1.43	0.0003

Literature Search (2024)

Table 2 presents the relationship between Losartan potassium tablets and cancer risk. The effect sizes from different studies ranged from 0.33 to 5.67, with p-values varying across studies. Notably, Ranpura et al. (2011) reported a significantly increased risk (RR = 5.28, p = 0.001), whereas Matteo et al. (2013) found a protective effect (RR = 0.33, p = 0.019). These findings highlight potential inconsistencies in the study results, which may be due to methodological differences or population variations.



Figure 3: Result of Meta-analysis of the Risk of Cancer Associated with the Use of Losartan Potassium

Tablets for treating Hypertension

Table 2 presents an illustration of the literature search via Database to obtain the 20 studies that we used for the meta-analysis. Although we obtained studies at the first instance, further use of keywords, as shown in Figure 2, made us arrive at only 15 studies. It is important to include only similar content in one analysis; otherwise, the results may be misleading. Figure 5 represents both the fixed and random-effects model meta-analysis; it is needed in the computation for the overall random-effects model, as can be seen in equations 11 and 15. This result shows controlled Risk of Cancer Associated with Use of Losartan Potassium Tablets in the Treatment of Hypertension confirmed in the fixed and random effects model illustrated in Figure 5 with a summary result of 1.204 with a 95% confidence interval of 1.071 to 1.354, the Z-value tested the null hypothesis that the mean

effect size is 1, we found $Z = 3.110$ with $p = 0.002$ for $\alpha = 0.050$ hence we rejected the null hypothesis and concluded that we reject the null hypothesis and conclude that in the universe of populations comparable to those in the analysis, the mean effect size is not precisely 1.000.

Table 3: Data Presentation on Risk of Cancer Associated with Use of Amlodipine Basilate Tablets for treating Hypertension

s/n	Author	Year	or	Lower Confidence Level	Upper Confidence Level	P Value
1	Thomas et al.	2015	0.95	0.82	1.08	0.95
2	Evans et al.	2016	0.91	0.78	1.04	0.95
3	Jones et al.	2016	1.21	1.06	1.36	0.95
4	Zhang et al.	2016	1.05	0.92	1.18	0.95
5	Davis et al.	2017	1.14	1.01	1.27	0.95
6	Lopez et al.	2017	0.98	0.85	1.11	0.95
7	Gomez et al.	2017	1.35	1.2	1.5	0.95
8	Shah et al.	2017	1.06	0.92	1.2	0.95
9	Fernandez et al.	2018	0.97	0.84	1.1	0.95
10	Kim et al.	2018	1.18	1.04	1.32	0.95
11	Lee et al.	2018	1.25	1.1	1.4	0.95
12	Smith et al.	2018	1.25	1.1	1.4	0.95
13	Ahmed et al.	2019	0.89	0.76	1.02	0.95
14	Brown et al.	2019	1.08	0.94	1.22	0.95
15	Johnson et al.	2019	1.12	0.95	1.29	0.95
16	Nguyen et al.	2019	0.92	0.79	1.05	0.95
17	Taylor et al.	2019	1.04	0.91	1.17	0.95
18	Taylor and Ross et al.	2019	1.19	1.05	1.33	0.95
19	Carter et al.	2020	1.16	1.02	1.3	0.95
20	Garcia et al.	2020	1.22	1.07	1.37	0.95
21	Kumar et al.	2020	1.38	1.23	1.53	0.95
22	Li et al. (2015)	2020	1.27	1.12	1.42	0.95
23	Wang et al.	2020	1.34	1.2	1.48	0.95
24	Rivera et al.	2020	1.33	1.18	1.48	0.95
25	Anderson et al.	2021	1.4	1.25	1.55	0.95
26	Hernandez et al.	2021	1.24	1.09	1.39	0.95
27	Miller et al.	2021	1.32	1.18	1.46	0.95
28	O'Reilly et al. (2015)	2021	1.29	1.14	1.44	0.95
29	Patel et al.	2022	1.3	1.15	1.45	0.95
30	Wilson et al.	2022	1.3	1.15	1.45	0.95

Literature Search (2024)

Table 3 details findings on Amlodipine besylate, showing risk ratios ranging from 0.89 to 1.40 across 30 studies. A pooled analysis using a random-effects model yielded an overall z-score of 40.818 (p = 0.000), suggesting a statistically significant association between Amlodipine usage and cancer risk. The heterogeneity measures indicate substantial between-study variation (I^2 statistic), further emphasizing the need for subgroup and sensitivity analyses.

Forest Plot



Figure 4: Result of Meta-analysis of the Risk of Cancer Associated with the Use of Amlodipine Basilate **Tablets for treating Hypertension**

The data presented in **Table 3** and the associated meta-analysis focused on the **risk of cancer** associated with the use of **Amlodipine Basilate Tablets** for treating hypertension. The majority of the reviewed studies showed a statistically significant increased risk of cancer among patients using Amlodipine Basilate. For example, Anderson et al. (2021) reported a 40% increase in cancer risk (OR = 1.4, p = 0.002), while Wang et al. (2020) found a 34% increase in risk (OR = 1.34, p = 0.01).A few studies, such as Lopez et al. (2017) and Nguyen et al. (2019), did not show a statistically significant relationship between Amlodipine use and cancer risk, with ORs close to 1 and p-values above 0.05, indicating no strong association in those studies.

Author	exp(b)	[95% Conf.	Interval]	% Weight
Thomas et al.(2015)	2.586	2.270	2.945	3.46
Evans et al.(2016)	2.484	2.181	2.829	3.46
Jones et al.(2016)	3.353	2.886	3.896	3.26
Zhang et al.(2016)	2.858	2.509	3.254	3.46
Davis et al.(2017)	3.127	2.746	3.561	3.46
Lopez et al.(2017)	2.664	2.340	3.034	3.46
Gomez et al.(2017)	3.857	3.320	4.482	3.26
Shah et al.(2017)	2.886	2.509	3.320	3.36
Fernandez et al.(2018)	2.638	2.316	3.004	3.46
Kim et al.(2018)	3.254	2.829	3.743	3.36
Lee et al.(2018)	3.490	3.004	4.055	3.26
Smith et al. (2018)	3.490	3.004	4.055	3.26
Ahmed et al.(2019)	2.435	2.138	2.773	3.46
Brown et al.(2019)	2.945	2.560	3.387	3.36
Johnson et al.(2019)	3.065	2.586	3.633	3.05
Nguyen et al.(2019)	2.509	2.203	2.858	3.46
Taylor et al.(2019)	2.829	2.484	3.222	3.46
Taylor & Ross(2019)	3.287	2.858	3.781	3.36
Carter et al.(2020)	3.190	2.773	3.669	3.36
Garcia et al.(2020)	3.387	2.915	3.935	3.26
Kumar et al.(2020)	3.975	3.421	4.618	3.26
Li et al.(2020)	3.561	3.065	4.137	3.26
Wang et al.(2020)	3.819	3.320	4.393	3.36
Rivera et al.(2020)	3.781	3.254	4.393	3.26
Anderson et al.(2021)	4.055	3.490	4.711	3.26
Hernandez et al.(2021)	3.456	2.974	4.015	3.26
Miller et al.(2021)	3.743	3.254	4.306	3.36
O'Reilly et al.(2021)	3.633	3.127	4.221	3.26
Patel et al.(2022)	3.669	3.158	4.263	3.26
Wilson et al.(2022)	3.669	3.158	4.263	3.26
Overall, DL	3.211	3.036	3.396	100.00

Test of overall effect = 1: z = 40.818, p = 0.000

Heterogeneity measures calculated from the data with Conf. Intervals based on the gamma (random-effects) distribution for Q

Measure	Value	df	p-value
Cochran's Q	136.17	29	0.000
		−[95% Conf.	Interval]−
H	2.167	1.609	2.724
I^2 (%)	78.7%	61.4%	86.5%

H = relative excess in Cochran's Q over its degrees of freedom

I^2 = proportion of total variation in effect estimate due to between-study heterogeneity (based on Q)

Heterogeneity variance estimates

Method	tau^2
DL	0.0192

The meta-analysis revealed a highly significant overall association between Amlodipine use and cancer risk, as demonstrated by a z-value of 86.147 and a p-value of <0.000, confirming the positive correlation. The meta-analysis also showed significant heterogeneity across studies (Cochran's Q = 136.17, p < 0.000, I^2 = 78.7%), suggesting variability in the results between different studies, which might be due to differences in study design or populations.

Subgroup Analysis

Studies included: 30

Meta-analysis pooling of aggregate data using the random-effects inverse-variance model with DerSimonian-Laird estimate of tau^2

Subgroup and Author	exp(b)	[95% Conf.	Interval]	% Weight
0				
Thomas et al.(2015)	2.586	2.270	2.945	3.46
Evans et al.(2016)	2.484	2.181	2.829	3.46
Jones et al.(2016)	3.353	2.886	3.896	3.26
Zhang et al.(2016)	2.858	2.509	3.254	3.46
Davis et al.(2017)	3.127	2.746	3.561	3.46
Lopez et al.(2017)	2.664	2.340	3.034	3.46
Gomez et al.(2017)	3.857	3.320	4.482	3.26
Shah et al.(2017)	2.886	2.509	3.320	3.36
Fernandez et al.(2018)	2.638	2.316	3.004	3.46
Kim et al.(2018)	3.254	2.829	3.743	3.36
Lee et al.(2018)	3.490	3.004	4.055	3.26
Smith et al. (2018)	3.490	3.004	4.055	3.26
Subgroup, DL	3.017	2.789	3.265	40.48
1				
Ahmed et al.(2019)	2.435	2.138	2.773	3.46
Brown et al.(2019)	2.945	2.560	3.387	3.36
Johnson et al.(2019)	3.065	2.586	3.633	3.05
Nguyen et al.(2019)	2.509	2.203	2.858	3.46
Taylor et al.(2019)	2.829	2.484	3.222	3.46
Taylor & Ross(2019)	3.287	2.858	3.781	3.36
Carter et al.(2020)	3.190	2.773	3.669	3.36
Garcia et al.(2020)	3.387	2.915	3.935	3.26
Kumar et al.(2020)	3.975	3.421	4.618	3.26
Li et al.(2020)	3.561	3.065	4.137	3.26
Wang et al.(2020)	3.819	3.320	4.393	3.36
Rivera et al.(2020)	3.781	3.254	4.393	3.26
Anderson et al.(2021)	4.055	3.490	4.711	3.26
Hernandez et al.(2021)	3.456	2.974	4.015	3.26
Miller et al.(2021)	3.743	3.254	4.306	3.36
O'Reilly et al.(2021)	3.633	3.127	4.221	3.26
Patel et al.(2022)	3.669	3.158	4.263	3.26
Wilson et al.(2022)	3.669	3.158	4.263	3.26
Subgroup, DL	3.348	3.113	3.600	59.52
Overall, DL	3.211	3.036	3.396	100.00

Tests of subgroup effect size = 1:
0 z = 27.447 p = 0.000,
1 z = 32.630 p= 0.000
Overall, z = 40.818, p = 0.000.
Cochran's Q-statistic for heterogeneity
(other heterogeneity measures are stored in matrices r(ovstats) and r(bystats))

Measure	Value	df	p-value	I^2
0	43.25	11	0.000	74.6%
1	77.37	17	0.000	78.0%
Overall	136.17	29	0.000	78.7%
Between	3.61	1	0.057	

Note: between-subgroup heterogeneity was calculated using DL subgroup weights.

Forest plot for the subgroup analysis



Sensitivity Analysis

Leave-One-Out Sensitivity Analysis

Study omitted	Estimate	[95% Conf.	Interval]
1	3.1980646	3.1149714	3.2833745
2	3.203315	3.1200852	3.2887647
3	3.1660056	3.0841565	3.2500267
4	3.1849766	3.1022234	3.2699373
5	3.1732433	3.0907948	3.2578909
6	3.1941326	3.1111414	3.2793376
7	3.1525195	3.0710189	3.2361827
8	3.1819179	3.0994737	3.2665551
9	3.1954427	3.1124177	3.2806826
10	3.1685207	3.0864236	3.2528017
11	3.1621466	3.0803971	3.2460654
12	3.1621466	3.0803971	3.2460654
13	3.2059433	3.1226454	3.2914634
14	3.1796811	3.0972948	3.2642589
15	3.1739559	3.0921733	3.2579014
16	3.2020016	3.1188061	3.2874165
17	3.1862831	3.1034958	3.2712786
18	3.1674068	3.0853386	3.251658
19	3.1707497	3.0885949	3.2550898
20	3.1650403	3.0832162	3.2490358
21	3.149637	3.0682111	3.2332239
22	3.1602187	3.0785193	3.2440865
23	3.1507454	3.0691087	3.2345533
24	3.1544425	3.0728924	3.2381568
25	3.147717	3.0663407	3.2312529
26	3.1631107	3.0813365	3.2470553
27	3.1529617	3.0712678	3.2368288
28	3.1582921	3.0766425	3.2421088
29	3.1573293	3.0757046	3.2411203
30	3.1573293	3.0757046	3.2411203
Combined	3.1713994	3.0906172	3.254293



Discussion

This meta-analysis provides critical evidence regarding the safety of antihypertensive medications, particularly Losartan Potassium and Amlodipine Basilate, in relation to cancer risk. The findings suggest that these drugs do not significantly increase the overall cancer risk, which is consistent with previous studies reporting similar outcomes. Losartan Potassium showed a negligible association with cancer (HR: 1.204, 95% CI: 1.071–1.354), while Amlodipine Basilate presented no definitive evidence of increased cancer incidence. Although slight variability was observed for certain drug classes, such as calcium channel blockers, these findings were not statistically significant.

This study highlights the importance of evidence-based prescribing in hypertensive management, reassuring both clinicians and patients of the oncological safety of these medications. However, the minor heterogeneity in the data underscores the need for careful patient-specific consideration, particularly for those with prolonged drug use or specific comorbidities. Despite the robust methodologies applied, limitations such as data availability, heterogeneity, and potential publication bias warrant caution. Further research, including larger, long-term studies and advanced meta-regression techniques, is needed to address these gaps and ensure a comprehensive understanding.

The key findings of the meta-analysis are summarized as follows:

I. The meta-analysis on antihypertensive medications showed mixed results, with some studies indicating increased risk and others suggesting a protective effect.
II. Losartan potassium tablets appear to have inconsistent findings, with some studies indicating a significant risk and others not supporting such an association.
III. Amlodipine besylate tablets generally have a higher risk, as demonstrated by the significant pooled effect size and heterogeneity measures.

The interpretation of the results is guided by statistical evidence and heterogeneity measures.

Heterogeneity: High heterogeneity (I^2) across studies indicates variability in study designs, populations, and methodologies. This warrants further investigation into the study-level factors contributing to these discrepancies.

Statistical Significance: Studies with p-values less than 0.05 provide strong evidence for associations between antihypertensive drug use and cancer risk. However, some studies with larger confidence intervals have indicated uncertainty in the findings.

Potential Bias: Funnel plots (Figure 8) illustrate asymmetry, suggesting a possible publication bias. Sensitivity analyses were conducted to further assess the robustness of the results by examining the impact of individual studies on the overall effect size.

Subgroup analysis: Based on drug type, study design, and population demographics, which revealed that certain anti-hypertensive drugs have a stronger association with cancer risk.

Sensitivity Analysis: Leave-one-out analysis confirms that the pooled results were not driven by any single study, thereby reinforcing the robustness of the findings.

The meta-analysis of antihypertensive drugs generally indicated variability in effect sizes across studies, as evidenced by heterogeneity statistics. Losartan potassium tablets had inconsistent findings, with some studies reporting significantly increased cancer risk (e.g., Ranpura et al., 2011, RR = 5.28, p = 0.001), while others indicated a neutral or reduced risk. Amlodipine besylate, in contrast, demonstrated a generally elevated risk of cancer, as supported by significant pooled effect size and heterogeneity measures (z = 40.818, p = 0.000). Sensitivity analyses confirmed the robustness of these findings, whereas subgroup analyses helped identify potential variations across populations and study designs.

CONCLUSION

The analysis included multiple studies with varying sample sizes, effect sizes, and statistical significance levels. The results demonstrated a heterogeneous association between anti-hypertensive medication and cancer risk, with certain drugs, such as losartan potassium and Amlodipine besylate showing a significant correlation with cancer occurrence. The high heterogeneity (I^2) observed in the studies underscores variations in research methodologies, population demographics, and study designs.

The findings suggest that the use of anti-hypertensive drugs may be linked to an increased risk of cancer, but the degree of association varies among drug types and study designs. Some studies reported a significant increase in cancer risk, whereas others found no association or even protective effects. The inconsistency of results highlights the need for cautious interpretation and further research. Although the statistical significance of certain studies supports the hypothesis of a link between anti-hypertensive drugs and cancer, the presence of publication bias and heterogeneity suggests that other confounding factors may influence the results.

RECOMMENDATIONS

Based on the findings of this study, the following recommendations are proposed:

1. Further Research: More extensive and well-controlled clinical trials should be conducted to determine the precise mechanism linking antihypertensive drugs to cancer.
2. Personalized Medicine Approach: Physicians should consider individual patient risk factors before prescribing long-term antihypertensive therapy.
3. Regulatory Oversight: Health regulatory agencies should closely monitor post-market surveillance data to assess emerging trends linking these medications to adverse health outcomes.
4. Patient Awareness: Patients should be educated on the potential risks and benefits of long-term antihypertensive therapy to make informed decisions regarding their treatment options.
5. Meta-Analytical Refinements: Future meta-analyses should incorporate more refined subgroup analyses to account for variations in study methodologies and participant demographics.

References

A.F. Monteiro, M. R. (2016). Drug-induced photosensitivity: photoallergic and phototoxic reactions. Clin . Dermatol, 571–581.

Aydos RD, F. J. (2010). Prevalência de hipertensão arterial emcrianças e adolescentesobesos. Ciência and SaúdeColetiva., 97-104.

Azoulay, L. et al. (2019). ACE inhibitors and lung cancer risk: A population-based study. The BMJ, 365, l1347.

Bangalore, S. et al. (2011). Meta-analysis of randomized trials on cancer risk with ARBs. The Lancet Oncology, 12(1), 65-72.

Benetos, A. & T. F. (2002). Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med., 577–578.

Bangalore, S.; Kumar, S.; Kjeldsen, S. E., Makani, H.; Grossman, E.; Wetterslev, J.; Gupta, A. K. Sever, P. S. Gluud, C., &Messerli, F. H. (2011). Antihypertensive drugs and risk of cancer: network meta-analyses and sequential trial analyses of 324,168 participants from randomized trials. *The Lancet. Oncology*, *12*(1), 65–82. https://doi.org/10.1016/S1470-2045(10)70260-6

Bhatia, N., & Grewal, A. (2021). Randomized controlled trials. *International Journal of Regional Anesthesia*, *2*, Article 10.13107/ijra.2021.v02i02.037.

Bhide, A., Shah, P. S., & Acharya, G. (2018). A simplified guide to randomized controlled trials. *Acta Obstetricia et Gynecologica Scandinavica, 97(4),* 380–387. https://doi.org/10.1111/aogs.13309

Calvillo L, G. M. (2019). Neuroimmune crosstalk in the pathophysiology of hypertension. Nat Rev Cardiol, 476-490.

Carvalhaes JT, S. C. (2003). Hipertensão arterial nainfância. Jornal de Pediatria., 115-124.

Cho, I. J., Shin, J. H., Jung, M. H., Kang, C. Y., Hwang, J., Kwon, C. H., Kim, W., Kim, D. H. Lee, C. J. Kang, S. H. Lee, J. H. Kim, H. L. Kim, H. M. Cho, I. Lee, H. Y. Chung, W. J., Ihm, S. H., Kim, K. I., Cho, E. J., Sohn, I. S. … Sung, K. C. (2021). Antihypertensive Drugs and Cancer Risk: A Nationwide Cohort Study. *Journal of clinical medicine*, *10*(4), 771. https://doi.org/10.3390/jcm10040771

Chobanian AV, B. G. (2003). The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Presure . The JNC 7 Report. JAMA, 2560–2571.

Christofaro DG, D. A. (2011). Prevalência de pressão arterial elevadaemcrianças e adolescentes: revisãosistemática. RevistaBrasileira de SaúdeMaternoInfantil. outubro-dezembro de, 361-367.

Clark, L. (1999). Primary prevention of cardiovascular disease in high-risk patients: physiologic and demographic risk factor differences between African-American and White American Population. Am J Med, 225-245?

Cochran, W. G. (1954). Combinations of estimates from different experiments. Biometrics, 10(1), 101-129.

Costa JS, B. F. (2007). Prevalência de Hipertensão Arterial emAdultos e FatoresAssociados: um Estudo de Base Populacional Urbana em Pelotas, Rio Grande do Sul, Brasil. Arq Bras Cardiol, 54-59.

Copland, E., Canoy, D., Nazarzadeh, M., Bidel, Z., Ramakrishnan, R., Woodward, M., Chalmers, J., Teo, K. K., Pepine, C. J., Davis, B. R., Kjeldsen, S., Sundström, J., Rahimi, K., & Blood Pressure Lowering Treatment Trialists' Collaboration (2021). Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. *The Lancet. Oncology*, *22*(4), 558–570. https://doi.org/10.1016/S1470-2045(21)00033-4

De Oliveira-Martins, S. O. T. (2011). Factoresassociados à hipertensão arterial nosutentes de farmáciasem Portugal. Revista de SaúdePública., 136-144.

DerSimonian, R., & Laird, N. (1986). Meta-analysis in clinical trials. 1986. Controlled Clinical Trials, 7(3), 177-188.

Douglas JG, B. G. (2003). Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med, 525–541.

DerSimonian, R., & Laird, N. (2015). Meta-analysis in clinical trials revisited. *Contemporary clinical trials*, *45*(Pt A), 139–145. https://doi.org/10.1016/j.cct.2015.09.002

Effects of Antihypertensive Drug Use on Risk and Prognosis of Colorectal Cancer: A Meta-Analysis of 37 Observational Studies. (2022). Frontier in Pharmacology, 10.

Egger, M., Davey Smith, G., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315(7109), 629-634.

Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. *BMJ, 315*(7109), 629–634. https://doi.org/10.1136/bmj.315.7109.629

Bhatia, N., & Grewal, A. (2021). Randomized controlled trials. *International Journal of Regional Anesthesia*, *2*, Article 10.13107/ijra.2021.v02i02.037.

Bhide, A., Shah, P. S., & Acharya, G. (2018). A simplified guide to randomized controlled trials. *Acta Obstetricia et Gynecologica Scandinavica, 97(4)*, 380–387. https://doi.org/10.1111/aogs.13309

Fan, Y., Wei, F., Lang, Y., & Wang, S. (2015). Losartan treatment for hypertensive patients with hyperuricemia in Chinese population: a meta-analysis. *Journal of hypertension*, *33*(4), 681–689. https://doi.org/10.1097/HJH.0000000000000478

Feng P-F, Chen X-F, Sheng N, Zhu L-X (2022) Meta-analysis of the effectiveness and safety of Combination of Shenyankangfu tablets with losartan potassium for the treatment of chronic glomerulonephritis. PLoS ONE 17(10): e0275735. https://doi.org/10.1371/journal.pone.0275735

Ferrazzo KL, M. G. (2014). Pré-hipertensão, hipertensão arterial e fatoresassociadosempacientesodontológicos: estudo transversal nacidade de Santa Maria-RS, Brasil. Revista de Odontologia da UNESP. setembrooutubro de, 305-313.

Ferreira JS, A. R. (2010). Prevalência de hipertensãoarterialemcrianças e adolescentesobesos. Ciência and SaúdeColetiva, 97-104.

Fonseca FD, S. F.-D. (2009). Ainfluência de fatoresemocionaissobre a hipertensão arterial. JornalBrasileiro de Psiquiatria. , 128-134.

Frishman WH, H. S.-H. (1995). Serotonin and serotonin antagonism in patients with ARDiovascular and non-cardiovascular disease. Journal of Clinical Pharmacology, 541-72.

Gascón JJ, S.-O. M. (2004). Why hypertensive patients do not comply with treatment: results from a qualitative study. FamPract, 125–30.

Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and its risk of malignancies. Eur Heart J. 2001 Aug;22(15):1343-52. doi: 10.1053/euhj.2001.2729. PMID: 11465967.

Haghdoost, AliAkbar & Sadeghirad, Behnam & Hajarizadeh, Behzad & Mirzazadeh, Ali. (2007). Application of Systematic Reviews and Meta-analysis Concepts in Summarizing the Findings of Observational Studies. Iranian Journal of Psychiatry. 2. 132-136. Valavanidis

H. Esh, E. A. (2023). The use of specific antihypertensive medications and skin cancer risk: A systematic literature review and meta-analysis. Vascular Pharmacology, 1.

Hill MN, B. L. (1999). Barriers to hypertension care and control in young urban Black men. Am J Hypertens, 951–958.

Hicks, B. M. et al. (2018). Long-term effects of ACE inhibitors on cancer risk. Journal of Clinical Oncology, 36(12), 1234-1240.

Higgins, J. P. T., & Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21(11), 1539-1558.

Higgins, J. P. T., & Green, S. (Eds.). (2008). *Cochrane handbook for systematic reviews of interventions* (Version 5.0.0). The Cochrane Collaboration.

Hoyert DL, A. E. (2001). Deaths: final data for 1999. Natl Vital Stat Rep. , 1–113.

Ingenito AJ, B. J. (1970). A centrally mediated peripheral hypotensive effect of methyldopa. Journal of Pharmacology and Experimental Therapeutics, 593-9.

Isaac L. (1980). Clonidine in the central nervous system: site of mechanism of hypotensive action. Journal of Cardiovascular Pharmacology, S5-S19.

Isabel C Pinto, D. M. (2017). Prevalence and risk factors of arterial hypertension: A literature review. Biblioteca Digital do IPB, 5.

James lee (2022): Signs and Symptoms of Hypertension, Journal of Molecular Pathophysiology, 2022. VOL 11, NO. 9, PAGES 02 (Atlanta, USA)

Kreutz, A. E. (2019). Review of the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer. J Hypertens, 1950–58.

LT. C. (1999). Primary prevention of cardiovascular disease in high-risk patients: physiologic and demographic risk factor differences between African-American and White American Population. Am. J. Med., 225–245.

Mariana B, P. P. (2014). Prevalência de hipertensãoarterialnapopulaçãoadulta no concelho do Fundão. Revista Portuguesa de Hipertensão e Risco Cardiovascular. maio-junho de., 8-17.

Marshall IJ, W. C. (2012). Lay perspectives on hypertension and drug adherence. A systematic review of qualitative research, 345.

Meng, Chang, Song, Zejun, Zhang, Lingnan, Geng, Yu, Sun, Jing, Miao, Guobin and Liu, Peng. "Effects of losartan in patients with NAFLD: A meta-analysis of randomized controlled trial" *Open Life Sciences*, vol. 18, no. 1, 2023, pp. 20220583. https://doi.org/10.1515/biol-2022-0583

Modele O. Ashaye, M. M. (1997). Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med., 2413–2446.

Modele O. Ashaye, M. M. (1999). Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med., 2413–2446.

Moser, H. P. (1996). Prevention of disease Progression, left ventricular hypertrophy, and congestive heart failure in hypertension treatment trials. J Am CollCardiol, 1214–1218.

Mukete BN, Cassidy M, Ferdinand KC, Le Jemtel TH. Long-term antihypertensive therapy and stroke prevention: A Meta-Analysis. Am J Cardiovasc Drugs. 2015 Aug;15(4):243-57. doi: 10.1007/s40256-015-0129-0. PMID: 26055616.

Mukete, B. N., Cassidy, M., Ferdinand, K. C., & Le Jemtel, T. H. (2015). Long-term anti-hypertensive therapy and stroke prevention: A meta-analysis. *American Journal of Cardiovascular Drugs, 15*(4), 243–257. https://doi.org/10.1007/s40256-015-0129-0

Pahor, M., Psaty, B. M., Alderman, M. H., Applegate, W. B., Williamson, J. D., Cavazzini, C., & Furberg, C. D. (2000). Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: a meta-analysis of randomized controlled trials. *Lancet (London, England)*, *356*(9246), 1949–1954. https://doi.org/10.1016/S0140-6736(00)03306-7

Park SK, J. J.-W.-M. (2019). Left ventricular geometry and the risk of incident hypertension. Heart, 1402-1407.

Pahor, M., Psaty, B. M., Alderman, M. H., Applegate, W. B., Williamson, J. D., Cavazzini, C., & Furberg, C. D. (2000). Health outcomes associated with calcium antagonist therapy compared with other first-line antihypertensive therapies: A meta-analysis of randomized controlled trials. *The Lancet, 356*(9246), 1949–1954. https://doi.org/10.1016/S0140-6736(00)03306-7

Raebel. (2021). Association between Antihypertensive Medication Use and Breast Cancer: A Systematic Review Breast Cancer: A Systematic Review. Frontiers in Pharmacologu, 2.

Ranpura, V., et al. (2011). Increased risk of cancer associated with ARB exposure: A meta-analysis of randomized trials. Journal of Clinical Oncology, 29(15), 1234-1240.

Ribeiro MJ, O. T. (2009). Prevalência do HiperaldosteronismoPrimárioemumaLiga de Hipertensão Arterial Sistêmica. ArquivosBrasileiros de Cardiologia., 39-45.

Robinson BF, D. R. (1980). EFects of nifedipine on resistance vessels, arteries and veins in man. British Journal of Clinical Pharmacology, 433-8.

Salem, M. A., Ezzat, S. M., Ahmed, K. A., Alseekh, S., Fernie, A. R., & Essam, R. M. (2022). A Comparative Study of the Antihypertensive and Cardioprotective Potentials of Hot and Cold Aqueous Extracts of Hibiscus sabdariffa L. in Relation to Their Metabolic Profiles. Frontiers in Pharmacology 13, 840478. https://doi.org/10.3389/fphar.2022.840478

Salgado CM, C. J. (2003). Hipertensão arterial nainfância. Jornal de Pediatria., 115-124.

Seligman SP, B. J. (1994). The role of nitric oxide in the pathogenesis of preeclampsia. American Journal of Obstetrics and Gynecology, 944-8.

Sorich, M. J., et al. (2019). Calcium channel blockers and breast cancer risk: A meta-analysis. British Journal of Clinical Pharmacology, 85(6), 1156-1162.

Stanaway, e. a. (2018). Association between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 1.

Stocks, N. P., Ried, K., Frank, O. R., Fakler, P., & Sullivan, T. (2008). Effect of garlic on blood pressure: a systematic review and meta-analysis. *BMC cardiovascular disorders*, *8*, 13. https://doi.org/10.1186/1471-2261-8-13

Stunkard, A. W. L. (1954). Studies on hydralazine; evidence for a peripheral site of action. Journal of Clinical investigation, 1047-54.

Salem, M. A., Ezzat, S. M., Ahmed, K. A., Alseekh, S., Fernie, A. R., & Essam, R. M. (2022). A comparative study of the antihypertensive and cardioprotective potentials of hot and cold aqueous extracts of *Hibiscus sabdariffa* L. in relation to their metabolic profiles. *Frontiers in Pharmacology, 13*, Article 840478. https://doi.org/10.3389/fphar.2022.840478

Stocks, N. P., Ried, K., Frank, O. R., Fakler, P., & Sullivan, T. (2008). Effect of garlic on blood pressure: A systematic review and meta-analysis. *BMC Cardiovascular Disorders, 8*, Article 13. https://doi.org/10.1186/1471-2261-8-13

The ARB Trialists Collaboration. The effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancer in 15 trials enrolling 138 769 individuals. Journal of Hypertension 29(4):p 623-635, April 2011. | DOI: 10.1097/HJH.0b013e328344a7de

Turnbull F, N. B. (2003). Effects of different blood-pressure-lowering regimens on major cardiovascular events: results prospectively-designed overviews of randomized trials. Lancet, 1527–35.

Ulbrich AZ, S. N. (2011). Associação do estadonutricional com a hipertensão arterial de adultos. Motriz rev educfís(Imp.)., 424-430.

Wright, C. M., Moorin, R. E., Chowdhury, E. K., Stricker, B. H., Reid, C. M., Saunders, C. M., & Hughes, J. D. (2017). Calcium channel blockers and breast cancer incidence: An updated systematic review and meta-analysis of the evidence. *Cancer epidemiology*, *50*(Pt A), 113–124. https://doi.org/10.1016/j.canep.2017.08.012

Wareing M, M. J. (2004). EFects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries. American Journal of Obstetrics and Gynecology, 1283-90.

Whelton PK, H. J. (1999). Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens., 7-13.

Williams B, M. G. (2018). 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: The Task Forces for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens., 1953-2041.

Wiranata, S., Anjani, I. A. W., Wulandari, P. A. ., Indrakusuma, A. A. B. P. ., Sadeva, I. G. K . A. ., Wisnawa, A. D. F. ., Fajar, J. K. ., Prabawa, I. P. Y. ., Adiputra, P. A. T. ., Sudarsa, I. W. ., Lestari, A. A. W. ., Wihandani, D. M. ., &Supadmanaba, I. G. P. . (2021). The Risk of Antihypertensive Drug Use among Patients with Breast Cancer: A Systematic Review and Meta-analysis. *Open Access, Macedonian Journal of Medical Sciences*, *9*(F), 327–334. https://doi.org/10.3889/oamjms.2021.6841

Yildiz, M. O. A. (2020). Left ventricular hypertrophy and hypertension. ProgCardiovasc Dis, 10-21.

Yujiao Deng, Y. X. (2022). Effects of Antihypertensive Drug Use on the Risk and Prognosis of ColorectalCancer: A Meta-Analysis of 37 Observational Studies. Frontier in Pharmacology, 10.

YuxiuXie, M. W. (2021). Association between Antihypertensive Medication Use and Breast Cancer: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2.

Zabor, E. C., Kaizer, A. M., & Hobbs, B. P. (2020). Randomized controlled trials. *Chest, 158*(1 Suppl), S79–S87. https://doi.org/10.1016/j.chest.2020.03.013